Conbercept and Dexamethasone intravitreal implant in treating diabetic macular edema with different optical coherence tomography types
10.3980/j.issn.1672-5123.2025.4.06
- VernacularTitle:康柏西普与地塞米松玻璃体内植入剂治疗不同OCT分型糖尿病性黄斑水肿
- Author:
Mei HU
1
;
Bo LI
1
;
Xinmiao HU
1
;
Yaqi HUANG
1
Author Information
1. Department of Ophthalmology, Xinyang Central Hospital, Xinyang 464000, Henan Province, China
- Publication Type:Journal Article
- Keywords:
Dexamethasone intravitreal implant;
Conbercept;
optical coherence tomography(OCT);
diabetic macular edema;
curative effect
- From:
International Eye Science
2025;25(4):551-557
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To investigate the efficacy and safety of dexamethasone versus conbercept in the treatment of diabetic macular edema(DME)with different optical coherence tomography(OCT)subtypes.METHODS: A total of 160 DME patients(160 eyes)admitted to our hospital from January 2021 to March 2023 were prospectively selected, and the patients were randomly divided into dexamethasone intravitreal implant group and conbercept group, with 80 cases(80 eyes)in each group, and DME patients were divided into 51 eyes with serous retinal detachment(SRD), 55 eyes with cystoid macular edema(CME), and 54 eyes with diffuse retinal thickening(DRT)according to OCT characteristics. The best corrected visual acuity(BCVA), central macular thickness(CMT), intraocular pressure and adverse reactions were compared before treatment and at 2, 3 and 6 mo postoperatively.RESULTS: There were differences in BCVA, CMT and intraocular pressure between the two groups at 2, 3 and 6 mo compared with those before operation(all P<0.05). There were differences in BCVA, CMT and intraocular pressure between the dexamethasone intravitreal implant group and the conbercept group in the treatment of patients with different types of DME(all P<0.05). The BCVA of patients with DRT and SRD types in the dexamethasone intravitreal implant group was improved at 3 and 6 mo after treatment compared with that in the conbercept group(all P<0.05). At 6 mo after treatment, the CMT of patients with DRT type in the dexamethasone intravitreal implant group was lower than that in the conbercept group(P<0.05). During the follow-up period, none of the patients experienced adverse events such as cataract exacerbation or retinal detachment.CONCLUSION: Both dexamethasone intravitreal implant and conbercept treatment can improve visual function and macular retinal morphology in patients with different OCT subtypes of DME with good safety, but the dexamethasone intravitreal implant is better than conbercept in the treatment of DRT type.
